Dose effects of continuous vinblastine chemotherapy on mammalian angiogenesis mediated by VEGF-A

References

• Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878–86
   PubMed Web of Science ®Google Scholar
• Hanahan D, Bergers G, Bergsland E. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105: 1045–7
   PubMed Web of Science ®Google Scholar
• Albertsson P, Lennernas B, Norrby K. On metronomic chemotherapy: Modulation of angiogenesis mediated by VEGF-A. Acta Oncol 2006; 45: 144–55
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27–31
   PubMed Web of Science ®Google Scholar
• Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 2002; 8: 221–32
   PubMed Web of Science ®Google Scholar
• Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15–24
   PubMed Web of Science ®Google Scholar
• Gately S, Kerbel R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 2001; 7: 427–36
   PubMed Web of Science ®Google Scholar
• Pasquier E, Honore S, Braguer D. Microtubule-targeting agents in angiogenesis: Where do we stand?. Drug Resist Update 2006; 9: 74–86
   PubMed Web of Science ®Google Scholar
• Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism. Eur J Cancer 1991; 27: 482–7
   PubMed Web of Science ®Google Scholar
• Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloids: Anti-vascular effects in a murine tumour. Eur J Cancer 1993; 29A: 1320–4
   PubMed Web of Science ®Google Scholar
• Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 1999; 94: 4143–55
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice. Cold Spring Harb Symp Quant Biol 2002; 67: 293–300
   PubMedGoogle Scholar
• Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4: 423–36
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Antiangiogenic therapy: A universal chemosensitization strategy for cancer?. Science 2006; 312(5777)1171–5
   PubMed Web of Science ®Google Scholar
• Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006; 108: 452–9
   PubMed Web of Science ®Google Scholar
• Stempak D, Seely D, Baruchel S. Metronomic dosing of chemotherapy: Applications in pediatric oncology. Cancer Invest 2006; 24: 432–43
   PubMed Web of Science ®Google Scholar
• Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: Microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002; 94: 883–93
   PubMed Web of Science ®Google Scholar
• Kerbel RS, Klement G, Pritchard KI, Kamen B. Continuous low-dose anti-angiogenic/ metronomic chemotherapy: From the research laboratory into the oncology clinic. Ann Oncol 2002; 13: 12–5
   PubMed Web of Science ®Google Scholar
• Lennernas B, Albertsson P, Lennernas H, Norrby K. Chemotherapy and antiangiogenesis–drug-specific, dose-related effects. Acta Oncol 2003; 42: 294–303
   PubMed Web of Science ®Google Scholar
• StCroix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, et al. Genes expressed in human tumor endothelium. Science 2000; 289(5482)1197–202
   PubMed Web of Science ®Google Scholar
• Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004; 64: 8249–55
   PubMed Web of Science ®Google Scholar
• Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer 2002; 2: 266–76
   PubMed Web of Science ®Google Scholar
• Norrby K. In vivo models of angiogenesis. J Cell Mol Med 2006; 10: 588–612
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis: An organizing principle for drug discovery?. Nat Rev Drug Discov 2007; 6: 273–86
   PubMed Web of Science ®Google Scholar
• Norrby K. Microvascular density in terms of number and length of microvessel segments per unit tissue volume in mammalian angiogenesis. Microvasc Res 1998; 55: 43–53
   PubMed Web of Science ®Google Scholar
• Norrby K. Angiogenesis: New aspects relating to its initiation and control. Apmis 1997; 105: 417–37
   PubMed Web of Science ®Google Scholar
• Naslund I, Norrby K. NO and de novo mammalian angiogenesis: Further evidence that NO inhibits bFGF-induced angiogenesis while not influencing VEGF165-induced angiogenesis. Apmis 2000; 108: 29–37
   PubMed Web of Science ®Google Scholar
• Lennernas B, Albertsson P, Damber JE, Norrby K. Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: A quantitative study. Apmis 2004; 112: 201–9
   PubMed Web of Science ®Google Scholar
• Albertsson P, Lennernas B, Norrby K. Chemotherapy and antiangiogenesis: Drug-specific effects on microvessel sprouting. Apmis 2003; 111: 995–1003
   PubMed Web of Science ®Google Scholar
• United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia. 2nd ed. Br J Cancer 1998;77:1–10.
   Google Scholar
• Norrby K. Vascular endothelial growth factor and de novo mammalian angiogenesis. Microvasc Res 1996; 51: 153–63
   PubMed Web of Science ®Google Scholar
• Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966; 50: 219–44
   PubMedGoogle Scholar
• Davidson IW, Parker JC, Beliles RP. Biological basis for extrapolation across mammalian species. Regul Toxicol Pharmacol 1986; 6: 211–37
   PubMed Web of Science ®Google Scholar
• Dixon RL. Problems in extrapolating toxicity data for laboratory animals to man. Environ Health Perspect 1976; 13: 43–50
   PubMed Web of Science ®Google Scholar
• Rahmani R, Zhou XJ. Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv 1993; 17: 269–81
   PubMedGoogle Scholar
• Zhou XJ, Martin M, Placidi M, Cano JP, Rahmani R. In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. II. Vinblastine and vincristine. Eur J Drug Metab Pharmacokinet 1990; 15: 323–32
   PubMed Web of Science ®Google Scholar
• Norrby K. Basic fibroblast growth factor and de novo mammalian angiogenesis. Microvasc Res 1994; 48: 96–113
   PubMed Web of Science ®Google Scholar
• Norrby K, Bergstrom S, Druvefors P. Hyperplasia and growth of the true mesentery in the diabetic rat. Acta Pathol Microbiol Immunol Scand [A] 1983; 91: 195–202
   PubMedGoogle Scholar
• Norrby K, Franzen L. A tissue model for the study of cell proliferation in vitro. In Vitro 1980; 16: 31–7
   PubMedGoogle Scholar
• Norrby K, Mattsby-Baltzer I, Innocenti M, Tuneberg S. Orally administered bovine lactoferrin systemically inhibits VEGF(165)-mediated angiogenesis in the rat. Int J Cancer 2001; 91: 236–40
   PubMed Web of Science ®Google Scholar
• Hayot C, Farinelle S, De Decker R, Decaestecker C, Darro F, Kiss R, et al. In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton. Int J Oncol 2002; 21: 417–25
   PubMed Web of Science ®Google Scholar
• Young SD, Whissell M, Noble JC, Cano PO, Lopez PG, Germond CJ. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin Cancer Res 2006; 12: 3092–8
   PubMed Web of Science ®Google Scholar
• Emmenegger U, Man S, Shaked Y, Francia G, Wong JW, Hicklin DJ, et al. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 2004; 64: 3994–4000
   PubMed Web of Science ®Google Scholar
• Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, Ben-David Y, et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005; 106: 3058–61
   PubMed Web of Science ®Google Scholar
• Poiley SM. Growth tables for 66 strains and stocks of laboratory animals. Lab Anim Sci 1972; 22: 758–79
   PubMedGoogle Scholar